A5063122523- Breast Cancer Treatment Studies
- Advanced Breast Cancer Therapies
- Cancer Genomics and Diagnostics
- HER2/EGFR in Cancer Research
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Cancer-related Molecular Pathways
- Radiomics and Machine Learning in Medical Imaging
- RNA modifications and cancer
- Esophageal Cancer Research and Treatment
- Prostate Cancer Treatment and Research
- Cancer Cells and Metastasis
- Radiopharmaceutical Chemistry and Applications
- Single-cell and spatial transcriptomics
- Ferroptosis and cancer prognosis
- Monoclonal and Polyclonal Antibodies Research
- Medical Imaging Techniques and Applications
- Estrogen and related hormone effects
- Cancer, Lipids, and Metabolism
- Renal cell carcinoma treatment
- Cytokine Signaling Pathways and Interactions
- PARP inhibition in cancer therapy
- Cancer Treatment and Pharmacology
- Retinoids in leukemia and cellular processes
- DNA Repair Mechanisms
Université Libre de Bruxelles
2020-2024
Institut Jules Bordet
2019-2024
IFOM
2024
Institute of Cancer Research
2018-2020
Royal Marsden NHS Foundation Trust
2018
Azienda Ospedaliero-Universitaria Careggi
2012-2018
Royal Marsden Hospital
2018
University of Florence
2013
We aimed to determine the distribution of intrinsic subtypes within HER2-low breast cancer (BC), and describe prognostic impact status on survival outcomes.This is a retrospective, observational study primary BC extracted from The Cancer Genome Atlas dataset. described PAM50 subtype according hormonal receptor (positive (HR+) negative (HR-)). Secondly, we assessed outcomes (progression-free interval (PFI), disease-free (DFI), overall (OS)).We analyzed 804 BCs, including 410 (51%) BCs (336...
Despite a proportion of renal cancer patients can experiment marked and durable responses to immune-checkpoint inhibitors, the treatment efficacy is widely variable identifying patient who will benefit from immunotherapy remains an issue. We performed prospective study investigate if soluble forms immune-checkpoints PD-1 (sPD-1), PD-L1 (sPD-L1), pan-BTN3As, BTN3A1, BTN2A1, could be candidate predict response blockade therapy. evaluated plasma levels in learning cohort metastatic clear cell...
Importance Biologic features may affect pathologic complete response (pCR) and event-free survival (EFS) after neoadjuvant chemotherapy plus ERBB2/HER2 blockade in -positive early breast cancer (EBC). Objective To define the quantitative association between pCR EFS by intrinsic subtype other gene expression signatures a pooled analysis of 3 phase trials: CALGB 40601, NeoALTTO, NSABP B-41. Design, Setting, Participants In this retrospective analysis, 1289 patients with EBC received either...
<p>Examples of the four classes HER2-PET/CT uptake.</p>
<p>Forest plots for pCR in I-SPY2, HER2-positive population, multivariable analysis controlling hormone receptor status and treatment arm.</p>
<p>Comparison of abundance scores immune populations and stromal cell types with MCP-counter according to A, ZrT class (dichotomized into “high” “low”), B, metabolic response.</p>
<div>AbstractPurpose:<p>The ZEPHIR clinical trial evaluated the role of [<sup>89</sup>Zr]trastuzumab-PET/CT (HER2-PET/CT) and 2-[<sup>18</sup>F]fluoro-2-deoxy-D-glucose PET/CT ([<sup>18</sup>F]FDG-PET/CT) in predicting outcomes patients with advanced HER2-positive breast cancer treated trastuzumab emtansine (T-DM1). In this study, we combined molecular/metabolic imaging transcriptomic data to investigate biological processes associated...
<p>Levels of TILs (%) according to ZrT class (dichotomized into “high” and “low”), metabolic response.</p>
<p>CONSORT diagram showing the patient selection for present analysis in ZEPHIR trial</p>
<p>Levels of stroma (%) according to ZrT class (dichotomized into “high” and “low”), metabolic response</p>
Objectives Sunitinib is the standard care for first‐line treatment of metastatic renal cell carcinoma. The aim this study was to determine whether a sunitinib regimen 50 mg/day 2‐weeks on/1‐week off could maintain same dose‐intensity as 4‐weeks on/2‐weeks schedule, and provide efficacy in terms objective response, progression‐free survival overall survival, while reducing drug‐related toxicity. Methods A total 31 patients with carcinoma received orally at dose until disease progression or...
Single cell technologies allow the interrogation of tumor heterogeneity, providing insights into evolution and treatment resistance. To better understand whether circulating cells (CTCs) could complement metastatic biopsies for genomic profiling, we characterized 11 single CTCs 10 pooled CTC samples at mutational copy number aberration (CNA) levels, compared these results with matched synchronous from 3 breast cancer patients triple-negative (TNBC), HER2-positive estrogen receptor-positive...
The identification of prognostic markers in patients receiving neoadjuvant therapy is crucial for treatment optimization HER2-positive breast cancer, with the immune microenvironment being a key factor. Here, we investigate complexity B and T cell receptor (BCR TCR) repertoires context two phase III trials, NeoALTTO CALGB 40601, evaluating paclitaxel trastuzumab and/or lapatinib women cancer. BCR features, particularly number reads clones, evenness Gini index, are heterogeneous according to...
Declines in prostate-specific antigen (PSA) levels at 12 wk are used to evaluate treatment response metastatic castration-resistant prostate cancer (mCRPC). PSA fall by ≥30% 4 (PSA4w30) has been reported be associated with better outcome a single-centre cohort study. To clinical relevance of early decline mCRPC patients treated next-generation hormonal treatments (NGHTs) such as abiraterone and enzalutamide. This was retrospective multicentre analysis. Eligible received NGHT for between 6...